The maintenance of an Outperform rating suggests continued confidence in Humana's performance, but the significant reduction in the price target from $400 to $280 indicates a more cautious outlook, likely due to changes in market conditions or company performance. This could lead to a short-term negative impact on the stock price as investors adjust their expectations.